![Stefan van den Eijnde](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stefan van den Eijnde
Directeur/Membre du Conseil chez Dutch Vaccines Group
Postes actifs de Stefan van den Eijnde
Sociétés | Poste | Début | Fin |
---|---|---|---|
Dutch Vaccines Group | Directeur/Membre du Conseil | 01/09/2009 | - |
LifetecZONe | Directeur/Membre du Conseil | 17/05/2010 | - |
Historique de carrière de Stefan van den Eijnde
Anciens postes connus de Stefan van den Eijnde
Sociétés | Poste | Début | Fin |
---|---|---|---|
MUbio Holding BV
![]() MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Corporate Officer/Principal | 01/01/2003 | 05/06/2013 |
Maastricht University | Directeur Technique/Scientifique/R&D | - | - |
NovoVacs BV | Fondateur | - | - |
Formation de Stefan van den Eijnde
University of Leiden | Graduate Degree |
Statistiques
Internationale
Pays-Bas | 7 |
Opérationnelle
Director/Board Member | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sectorielle
Consumer Services | 3 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
MUbio Holding BV
![]() MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
NovoVacs BV | |
Dutch Vaccines Group | |
LifetecZONe |
- Bourse
- Insiders
- Stefan van den Eijnde
- Expérience